A research team at Roswell Park Comprehensive Cancer Center in Buffalo has reported promising results from a phase 1 clinical trial for patients receiving donor blood stem cell transplants. The study tested adding the targeted therapy VIC-1911 to the standard post-transplant regimen of cyclophosphamide and sirolimus…